AstraZeneca PLC (NASDAQ:AZN) Shares Acquired by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. boosted its position in shares of AstraZeneca PLC (NASDAQ:AZNFree Report) by 5.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,726,180 shares of the company’s stock after purchasing an additional 132,970 shares during the period. Envestnet Asset Management Inc. owned approximately 0.09% of AstraZeneca worth $183,608,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in AZN. Anchor Investment Management LLC bought a new stake in AstraZeneca in the 4th quarter valued at about $26,000. Compagnie Lombard Odier SCmA bought a new stake in AstraZeneca in the 4th quarter valued at about $27,000. Nemes Rush Group LLC lifted its position in AstraZeneca by 375.6% in the 3rd quarter. Nemes Rush Group LLC now owns 428 shares of the company’s stock valued at $29,000 after purchasing an additional 338 shares during the last quarter. Jones Financial Companies Lllp lifted its position in AstraZeneca by 86.7% in the 4th quarter. Jones Financial Companies Lllp now owns 506 shares of the company’s stock valued at $34,000 after purchasing an additional 235 shares during the last quarter. Finally, Northwest Financial Advisors bought a new stake in AstraZeneca in the 4th quarter valued at about $34,000. 20.35% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

AZN has been the topic of several recent research reports. Argus lifted their price objective on shares of AstraZeneca from $80.00 to $85.00 and gave the company a “buy” rating in a research report on Thursday, May 30th. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Tuesday, April 16th. The Goldman Sachs Group initiated coverage on shares of AstraZeneca in a research note on Thursday, May 30th. They set a “buy” rating and a $97.00 target price on the stock. Finally, BMO Capital Markets raised their target price on shares of AstraZeneca from $80.00 to $82.00 and gave the company an “outperform” rating in a research note on Friday, April 26th. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, AstraZeneca currently has an average rating of “Moderate Buy” and an average price target of $88.00.

Check Out Our Latest Analysis on AstraZeneca

AstraZeneca Stock Down 1.0 %

AstraZeneca stock opened at $80.02 on Friday. The stock has a market cap of $248.10 billion, a price-to-earnings ratio of 39.23, a PEG ratio of 1.45 and a beta of 0.48. The company has a current ratio of 0.89, a quick ratio of 0.70 and a debt-to-equity ratio of 0.73. The company’s 50-day moving average price is $74.21 and its two-hundred day moving average price is $68.77. AstraZeneca PLC has a 52 week low of $60.47 and a 52 week high of $80.86.

AstraZeneca (NASDAQ:AZNGet Free Report) last announced its quarterly earnings data on Thursday, April 25th. The company reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.95 by $0.08. The company had revenue of $12.68 billion for the quarter, compared to analysts’ expectations of $11.92 billion. AstraZeneca had a net margin of 13.30% and a return on equity of 30.42%. On average, analysts expect that AstraZeneca PLC will post 4.04 EPS for the current fiscal year.

About AstraZeneca

(Free Report)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

Featured Stories

Institutional Ownership by Quarter for AstraZeneca (NASDAQ:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.